Today's brief highlights the expanding clinical footprint of personalized neoantigen vaccines across solid tumors and hematologic malignancies, with new trials launching in pancreatic, breast, and prostate cancers.
Concurrently, methodological advances in AI-driven epitope prediction and standardized bioinformatics workflows are addressing the computational bottlenecks of vaccine design.
West China Hospital has launched a Phase I dose-escalation study for PAN-NeoVax, an AI-designed pan-cancer neoantigen mRNA vaccine delivered via intratumoral injection. The trial targets advanced solid tumors post-second-line therapy, utilizing a 3+3 design to assess safety and preliminary efficacy of lipid nanoparticle-formulated mRNA.
Seqker Biosciences has completed a Phase I/II trial of a personalized neoantigen peptide vaccine for advanced solid tumors. The study leveraged whole exome and RNA sequencing to identify patient-specific mutations, aiming to evaluate safety, immunogenicity, and clinical efficacy in a population with limited treatment alternatives.
The Jaime Leandro Foundation for Therapeutic Cancer Vaccines is conducting a Phase 1b/2 multi-center study of synthetic long peptide neoantigen vaccines. The trial is currently enrolling by invitation to assess safety and efficacy in patients with local or metastatic solid tumors.
A new Nature publication reports that personalized RNA neoantigen vaccines successfully stimulated T cell responses in pancreatic cancer patients. This finding provides clinical evidence supporting the immunogenic potential of RNA-based platforms in this historically difficult-to-treat malignancy.
Anda Biopharmaceutical has opened an expanded access program for PCNAT-01, a personalized tumor neoantigen peptide vaccine, for patients with resected pancreatic ductal adenocarcinoma. The program targets disease-free patients post-surgery and adjuvant therapy to reduce recurrence risk, subject to regulatory and sponsor review.
Dana-Farber Cancer Institute is recruiting for a Phase I trial of a personalized neoantigen vaccine in treatment-naïve, asymptomatic patients with IGHV-unmutated chronic lymphocytic leukemia (CLL). The regimen combines the vaccine with Poly-ICLC, cyclophosphamide, and pembrolizumab.
NEC Bio B.V. is recruiting for a Phase I/II trial of NECVAX-NEO1, a personalized neoantigen-targeting vaccine, in neoadjuvant triple-negative breast cancer. The study evaluates the vaccine in combination with standard-of-care anti-PD-1 therapy and chemotherapy, with potential post-surgical extension.
Centre Georges Francois Leclerc is initiating a Phase I study of ODI-2001, a personalized DNA neoantigen vaccine combined with a Modified Vaccinia Ankara adjuvant and ipilimumab. The trial targets metastatic or locally advanced colon and pancreatic cancers, starting with dose escalation to determine the maximum tolerated dose.
Changhai Hospital is testing YS247, a personalized neoantigen-pulsed dendritic cell vaccine, for metastatic castration-resistant prostate cancer. The Phase I study aims to determine safety and the maximum tolerated dose across three dose levels, while monitoring PSA levels and immune stimulation.
A Phase 1 trial published in Nature investigates adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma. The study explores the feasibility and immunogenicity of DNA-based platforms in the context of standard adjuvant therapy for this aggressive brain cancer.
Researchers present ImmunoNX, an end-to-end bioinformatics workflow for neoantigen prediction and vaccine design, built on WDL and Cromwell. The protocol has supported over 185 patients across 11 trials, integrating tumor DNA/RNA sequencing with consensus variant calling and a two-stage immunogenomics review process.
pVACview is introduced as an interactive visualization tool designed to streamline neoantigen prioritization and selection. The tool addresses the complexity of navigating multiple prediction algorithms, transcript annotations, and peptide registers, facilitating more efficient candidate selection for downstream clinical applications.
The NEO model utilizes a stacking ensemble of Feed Forward and Recurrent Neural Networks with LSTM architecture to optimize neoepitope binding predictions. By aggregating scores from state-of-the-art models like MHCFlurry and NetMHCstabpan, NEO aims to accelerate and reduce the cost of identifying optimal neoepitopes for personalized vaccines.
A new Nature paper introduces NeoPrecis, a method that enhances immunotherapy response prediction by integrating qualified immunogenicity data with clonality-aware neoantigen landscapes. This approach aims to improve the accuracy of selecting neoantigens that are most likely to elicit a therapeutic T-cell response.
A comprehensive review in EuropePMC synthesizes the current state of neoantigen-based T cell vaccines, covering design strategies, therapeutic barriers, and clinical advances. The article examines mechanisms across mRNA, peptide, and dendritic cell platforms, highlighting synergies with checkpoint blockade and the challenges of immunosuppressive tumor microenvironments.